THE C3H/HeJ strain of mice obtained from the Jackson Laboratory (Bar Harbor, Maine, U.S.A.) shows a high incidence of spontaneous mammary cancer (Green, 1966) . Bacillus Calmette Guerin (BCG) is an effective immunopotentiator and has been used as an adjuvant to control neoplastic growth in both experimental animals and humans. In all probability, it exerts this action by enhancing the macrophage response to foreign antigen (Hersh, Gutterman and Mavleget, 1977) .
A multitude of papers reviewed by Bardawil and Troy (1959) attests to the various effects produced in experimental animals by immunization with heterologous antisera to placental homogenates. The use of placental tissue alone for immunization has also been examined (Jones, Ing and Kaye, 1972) . The effect of a combined vaccine containing autogenous placenta and BCG on the incidence of autochthonous mammary cancer in a highly susceptible animal has not hitherto been adequately investigated and is the subject of this study.
Tumour cells possess at least 2 antigens at the cell surface which elicit cellular immune reaction: foetal antigen and tumour-specific transplantation antigen (TSTA). The current belief is that these 2 antigens may not be distinct entities but are both the expression of normal cellular components present during normal embryonic development (Coggen and Anderson, 1972 given a single s.c. injection of the combined vaccine. This vaccine was individually prepared for each animal, and contained the total prepared cellular fragments of single placenta from the donor, mixed with the same quantity of BCG as in Group B. The mice were examined every third day to detect and recordl the presence and development of mammary-glandmalignancies. The age of the animal at the time of the first discernible appearance of a malignant mammary tutmour and at the time of its death was recor(led. Only female breeding mice were studied. Tumour-s other than malignant mnamnmary growths were excluded from this study.
(Crotup A and B eacth ha(d 2 otherwise The incidences of autochthonous tumour in the 3 groups are shown in the Table.
The control group followed precisely the tumour incidence predicted by the Jackson Laboratory, Group B, which contained BCG alone, showed a delay of one month in tumour development, with the incidence at 14 months being 6% less than in Group A. The group that was given the combined vaccine (C) showed a delay of 5 months before tumours were evident and the incidence at 14 months was 530 less than in the control group. Logrank values using the Peto and Pike derivatives give x2 for Group A vs Group B of 0X4624 with the probability of 0 5. This suggests that the BCG vaccine alone has no statistically acceptable effect on the incidence of malignant tumours. Logrank values for Group A vs Group C give a x2 of 7 8867 (P<001). Consequently, it can be assumed that the combined vaccine has a highly significant effect in reducing the incidence of malignant mammary tumours. In addition, the interval from the initial detection of a malignancy to the death of the animal varied in the 3 groups. On average, Group B mice survived 20% longer with the tumour than did the cancerous mice in Group A, whereas the mice in Group C survived 60% longer with the tumour than did those in Group A. (Weintraub and Rosen, 1971 ). In addition, chorionic gonadotrophin production also occurs in a variety of tumours (Rosen et al., 1968) . Finally, cancers produce a factor which stimulates the host to provide the blood supply for the neoplastic tissue. This tumour angiogenesis factor (TAF) appears to be crucial to the growth of many tumours, and is also found in the placenta (Folkman, 1972) .
Theoretically, there are a number of ways in which the combined placenta-BCG vaccine could reduce the incidence of malignancy. The vaccine could induce a heightened state of immunity against antigens common to both placental cells and cancerous cells. If this shared antigen is present on the surface membrane, a cell-mediated immune response may account for the reduced incidence. If, however, the common antigen is a cellmediated extracellular agent such as TAF, a humoral antibody is implicated. In either case the vaccine functions prophylactically in producing an immunity against the future development of cancer cells exhibiting antigens that it shares with the placenta.
It is also possible that the placenta contains a maternally derived oncogenic virus or viruses. The placenta vaccine is then producing immunity against a oncogenic virus that the animal may be destined to encounter during adult life. It is difficult to place a milk-born Bittnertype virus in this category since all the mice have already been exposed to the milk for 3 weeks before receiving any vaccine. Finally, the vaccine may reduce the sensitivity of breast tissue to the carcinogenic action of endogenous breast-stimulating hormones.
The enormous advantage that term placenta provides in promoting immunity against malignancy is that this is the only tissue which becomes obsolete at the moment of every mammal's birth and consequently is dispensible.
